GlaxoSmithKline and Corixa Sign on as National Sponsors of The Leukemia & Lymphoma Society's Light The Night Walk

GlaxoSmithKline and Corixa Sign on as National Sponsors of The
Leukemia & Lymphoma Society's Light The Night Walk 


WHITE PLAINS, N.Y., Sept. 21  /PRNewswire/ -- Pharmaceutical companies
GlaxoSmithKline and Corixa Corporation have signed on as national sponsors of
The Leukemia & Lymphoma Society's Light The Night Walk. The companies will
provide support to help the Society advance its mission: to cure leukemia,
lymphoma, Hodgkin's disease and myeloma and improve the quality of life of
patients and their families.

"We're thrilled to have GlaxoSmithKline and Corixa as national sponsors of this
year's Light The Night Walk," said Dwayne Howell, President and C.E.O. of The
Leukemia & Lymphoma Society. "We appreciate their generosity and are grateful
for their commitment to help make this year's event the best yet."

Light The Night is the Society's annual fall campaign held in hundreds of
communities around the country to raise money for blood cancer research and
patient services. Teams of co-workers, families and friends walk together in
twilight holding illuminated balloons -- white for survivors and red for
supporters. The walk commemorates lives touched by cancer. Last year, the walk
raised more than $18 million. This year's goal is $23 million.

"As important therapeutic advances are made against non-Hodgkin's lymphoma and
other blood-borne cancers, the role that The Leukemia & Lymphoma Society plays
in educating and informing patients and their caregivers about their disease
and its treatment is absolutely critical," said Steven Gillis, PhD, Chairman
and CEO of Corixa Corporation.  "The dedicated employees of Corixa Corporation
and GlaxoSmithKline are pleased to join the unwavering efforts of the thousands
of Light The Night volunteers around the country in this important event."

"GlaxoSmithKline, together with Corixa Corporation, is proud to sponsor The
Leukemia & Lymphoma Society's important annual fundraising event," said Kevin
Lokay, Vice President, GlaxoSmithKline Oncology.  "The Light The Night Walks
held in communities around the country help to raise awareness of blood- borne
cancers, such as lymphoma, and to provide invaluable information and services
to patients."

Corixa and GlaxoSmithKline co-market the anti-cancer radioimmunotherapy Bexxar
(Tositumomab and Iodine I 131 Tositumomab) in the United States.
Radioimmunotherapy represents a novel approach to the treatment of non-
Hodgkin's lymphoma. For more information, call the Society's Information
Resource Center at [phone].

Register for Light The Night Today

Registering for a Light The Night Walk event in your community is easy. Call
(877) LTN-WALK or visit http://www.lightthenight.org/.

About Corixa

Corixa (NASDAQ:CRXA) is a developer of immunotherapeutics with a commitment to
treating and preventing cancer and infectious diseases by understanding and
directing the immune system. On June 30, 2003, Corixa announced that the FDA
approved the BEXXAR(R) therapeutic regimen (Tositumomab and Iodine I 131
Tositumomab) for the treatment of patients with CD20 positive, follicular NHL,
with and without transformation, whose disease is refractory to Rituximab and
has relapsed following chemotherapy.

Corixa is focused on immunotherapeutic products and has a broad technology
platform enabling both fully integrated vaccine design and the use of its
separate, proprietary product components on a standalone basis. In addition to
BEXXAR, Corixa currently has multiple programs in clinical development,
including several product candidates that have advanced to and through late
stage clinical trials. The company partners with numerous developers and
marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM)
technology with the goal of making its potential products available to patients
around the world. Corixa was founded in 1994 and is headquartered in Seattle,
with additional operations in Hamilton, Mont., and South San Francisco. For
more information, please visit Corixa's Web site at http://www.corixa.com/.

About GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) is one of the world's leading research-based
pharmaceutical and healthcare companies. GlaxoSmithKline is committed to
improving the quality of human life by enabling cancer patients to do more,
feel better and live longer. For more information, visit http://www.gsk.com/.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, is the
world's largest voluntary health organization dedicated to funding blood cancer
research and providing education and patient services. The Society's mission is
to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and to improve the
quality of life of patients and their families. Since its founding in 1949, the
Society has invested more than $360 million in research specifically targeting
leukemia, lymphoma and myeloma. Last year alone, the Society made more than
812,000 contacts with patients, caregivers and healthcare professionals through
services provided at its home office and by its 63 chapters nationwide. For
more information, visit http://www.lls.org/.

   Contacts:
   Jon Garbo, The Leukemia & Lymphoma Society, [phone]
   Jim DeNike, Corixa Corporation, [phone]
   Danielle Halstrom, GlaxoSmithKline, [phone]
   Kristin Paulina, Sam Brown Communications, [phone]


DATASOURCE: The Leukemia & Lymphoma Society



CONTACT:  Jon Garbo, The Leukemia & Lymphoma Society, [phone];

Jim DeNike, Corixa Corporation, [phone]; Danielle Halstrom,

GlaxoSmithKline, [phone]; Kristin Paulina, Sam Brown Communications,

[phone]



Web site:  http://www.lightthenight.org/

http://www.corixa.com/

http://www.gsk.com/

http://www.lls.org/

Copyright